Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Melanotan II

Melanotan II is a cyclic alpha-MSH analogue with activity at multiple melanocortin receptors; it is distinct from afamelanotide and bremelanotide products. A 1996 phase-I pilot enrolled three men and reported pigmentation plus nausea, fatigue, yawning, and erections. This sample is far too small for broad efficacy or safety conclusions.

Aliases reviewed
MT-II, MT2
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
LimitedOne three-person pilot study from 1996.
Animal/cell
Not rated
Approved medicine
None foundScope: the U.S. sources reviewed.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. Early studies examined pigmentation and erectile responses, while current concern includes uncontrolled products and receptor-wide effects.

Identity

Melanotan II is a cyclic alpha-MSH analogue with activity at multiple melanocortin receptors; it is distinct from afamelanotide and bremelanotide products.

Biological mechanism or research interest

Early studies examined pigmentation and erectile responses, while current concern includes uncontrolled products and receptor-wide effects.

Verified approved human uses

No FDA-approved Melanotan II medicine was identified in the reviewed sources.

Investigational human evidence

A 1996 phase-I pilot enrolled three men and reported pigmentation plus nausea, fatigue, yawning, and erections. This sample is far too small for broad efficacy or safety conclusions.

Tanning, appetite, and sexual-function claims outpace the limited, old, small human evidence.

Human versus animal or cell evidence

Potent receptor activity and laboratory findings do not establish a safe consumer formulation.

Limitations and known risks

FDA summarizes case reports including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism; causality and product identity can be uncertain.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.